1 / 26

Text

IMAGING with RADIOPHARMACEUTICALS. Functional molecular specificity for disease detection and “follow-up” Durval C. Costa MD, MSc, PhD, FRCR Director Nuclear Medicine-Radiopharmacology Champalimaud Clinical Centre Champalimaud Foundation. Text. IMAGING clinical practice & research.

duane
Télécharger la présentation

Text

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IMAGING with RADIOPHARMACEUTICALS Functional molecular specificity for disease detection and “follow-up” Durval C. Costa MD, MSc, PhD, FRCR Director Nuclear Medicine-Radiopharmacology Champalimaud Clinical Centre Champalimaud Foundation Text

  2. IMAGING clinical practice & research

  3. IMAGES in MEDICINE (resolution: spatial vs contrast/concentration) Method CT MRI MRSI SPECT PET HFUS Optical Minimum Detectable Size (Ø) 1 ~ 2 mm 1 ~ 2 mm 7 mm (~3 mm at 3T) 4 ~ 6 mm 3 ~ 5 mm < 1 mm 0.02 mm Minimum Detected Molar Cells (n) mM 400,000 400,000 1,000,000 pM500,000 pM300,000 100,000 1000

  4. IMAGES with RADIOPHARMACEUTICALS - Cellular functional Specificity - Fluorodeoxyglucose (FDG) is phosphorylated to FDG-6-PO4 by hexokinase. Since the activity of glucose-6-phosphatase is negligible, FDG-6-phosphate is essentially trapped in tumor cells. Unfortunately it is also trapped in activated macrophages. Fluorothymidine (FLT) is phosphorylated by thymidine kinase to FLT-6-PO4 and accumulates in tumor cells. It is described as a marker of cell proliferation. Czernin J and Phelps ME.. Annu Rev Med, 2002; 53: 89-112.

  5. IMAGES with RADIOPHARMACEUTICALS clinical and research applications • Imaging and Molecular Medicine • Radiopharmaceuticals for DIAGNOSIS • Radiopharmaceuticals for THERAPY • Radiopharmaceuticals for ASSESSMENT and MONITORING response to THERAPY • Radioligands for R & D – new THERAPIES (pharmacokinetics and pharmacodynamics)

  6. IMAGES with RADIOPHARMACEUTICALS Case 01 74 y old man; Radical prostatectomy 10 ys ago for carcinoma; Bone Scintigraphy – multiple bone metastases; ULTRASSOUN images – normal, i.e. sem no loco-regional recurrence; 17-July-2006 Alkaline Phosphatase 125 U/L (N 40-150) Acid Phosphatase 4,3 U/L (N 0,0-6,5) Prostatic fraction 0,6 U/L (N < 2,6) PSA (prostate specific antigen) 0,33 ng/ml (N < 5) Proteina C reactiva 0,4 ng/ml (N 0,0-0,5)

  7. IMAGES with RADIOPHARMACEUTICALS Case 01 24-July-2006

  8. 23-July-2007 2nd IODO-131 THERAPY (7,4 GBq, i.e. 200 mCi) IMAGES with RADIOPHARMACEUTICALS Case 01 Pathology from biopsy – Thyroid carcinoma; Total Thyroidectomy; 13-November-2006 1st IODO-131 THERAPY (7,4 GBq, i.e. 200 mCi)

  9. PET-CT camera Gama camera Outpatient Inpatient Radiopharmaceuticals Cyclotron Generators Radionuclides Nuclear Reactor RADIOPHARMACEUTICALS NUCLEAR/MOLECULAR MEDICINE Diagnosis Therapy

  10. RADIOPHARMACEUTICALS NUCLEAR/MOLECULAR MEDICINE Spatial resolution – detectable minimum lesion size!?

  11. Function Clinical Ratings Time RADIOPHARMACEUTICALS Diagnose EARLY to IMPROVE Outcome!

  12. RADIOPHARMACEUTICALS - PET Cost-Savings BENEFIT analyses! Ken A. Miles. An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by positron emission tomography. Australasian Radiology, 2001; 45: 9-18.

  13. RADIOPHARMACEUTICALS - PET Cost-Savings BENEFIT analyses!

  14. PET with FDG in ONCOLOGY UTILITY in CLINICS • Diagnosis and “grading” of malignant disease • Definition of disease extent • staging and restaging • Identification and localisation of disease foci • unknown primary (paraneoplastic syndromes) • Evaluation and monitoring of response to therapy • Identification of recurrent disease in comparison with “raising” tumour markers and anatomic/structural changes (CT and MR) • Guide for biopsy • Therapy guidance and “management”

  15. PET with FDG in ONCOLOGY Overall results – sensitivity and specificity • Sensitivity - 84% (based on 18 402 patient studies) • Specificity - 88% (based on 14 264 patient studies) • Average management change across all aplications • 30% (based on 5 062 patients) • Sensitivity range 84% - 87% • Specificity range 88% - 93% • Accuracy range 87% - 90% Gambhir SJ, Czernin J, Schwimmer J, et al. A Tabulated Summary of the FDG PET Literature. J Nucl Med, 2001; 42: 1S-93S. [www.snm.org]

  16. SCC Oral cavity FDG +ve FET +ve FDG +ve FET -ve RADIOPHARMACEUTICALS Distinction between TUMOUR and inflammation 21 consecutive pts (3 women and 18 men, age range 41 to 80 y) with suspected squamous head and neck cancer. FDG Fluorodeoxyglucose FET O-(2-[18F]fluoroethyl)-L-tyrosine Chronic inflammation Pauleit D, Zimmermann A, Stoffels G, et al. J. Nucl Med, 2006; 47: 251-261.

  17. RADIOPHARMACEUTICALS The future requests planning … measures and ACTION 11C 18F 3H 15O Molecular Chemistry Cyclotron and “Production Facility”

  18. FDG AC RADIOPHARMACEUTICALS The future requests planning … measures and ACTION 13 of 22 pts with serum PSA > 3ng/mL had positive AC PET findings. Only 1 of 24 pts with serum PSA ≤ 3ng/mL had positive findings. 11C-Acetate 77-y-old man with PSA relapse and serum PSA value of 10.5 ng/mL 8 y after radical prostatectomy and 5 y after salvage external-beam radiation therapy. Histologic diagnosis showed Gleason score of 8 at surgery. CT scan negative. Oyama N, et al. J Nucl Med, 44 (4): 549-555; 2003

  19. RADIOPHARMACEUTICALS … differential diagnosis of DEMENTIA AD FTD Accuracy = 0.778 (Exatidão = 0.778) Accuracy = 0.875 (Exatidão = 0.875)

  20. RADIOPHARMACEUTICALS … labelling β-Amyloid pathology “in vivo”. 18F-florbetapir (18FAV-45) 18F-flutemetamol (18FGE067) 18F-florbetaben (18F-BAY94-9172) Benzothiazole11C - 6-OH-BTA-1 (also known as 11C - PIB) Binds to Aβ 1-40 and Aβ 1-42 fibrils Stilbene11C -SB-13 99Tcm-MAMA-chrysamine G (analog of Congo red) Labels Aβ 10-43

  21. RADIOPHARMACEUTICALS - positive markers of disease … labelling β-Amyloid pathology “in vivo”. 11C-PIB N-Methyl-11C-2-(4´-methylamino-phenyl)-6-hydroxy-benzothiazole or 11C-6-OH-BTA-1 Average radiochemical yield - 20%; Synthesis time - 45 min; Radiochemical purity - 98%. Ng S, et al. J Nucl Med 2007; 48: 547-552.

  22. KS, 62 y old male; bil. tremor, rigity, akinesia, no falls, no visual hallucinations H & Y=3.0; MMSE=27/30; CAMCOG=101/107 123I-FP-CIT 123I-IBZM dopamine D2 post-synaptic receptor marker pre-synaptic transporter marker R Idiopathic Parkinson’s Disease (IPD) RADIOPHARMACEUTICALS … imaging neuropathology “in vivo”. INM

  23. A D N V E T Drug induced parkinsonism IPD DLB Schizophrenia + PD RADIOPHARMACEUTICALS … imaging neuropathology “in vivo”. AD= Alzheimer’s disease; DLB= dementia with Lewy bodies; ET= Essential benign tremor; IPD= idiopathic Parkinson’s disease; NV= normal volunteer INM INM

  24. Coronary angiography confirms LMS occlusion (A), with patent RCA (B), right-to-left collateral circulation (C) and normal LV contractile function (D) RADIOPHARMACEUTICALS … in Nuclear Cardiology – Myocardial Viability

  25. RADIOPHARMACEUTICALS … in Nuclear Cardiology – Myocardial Viability Patologias associadas Toxic Autonomous Adenoma of the THYROID Multiple pulmonary emboli

  26. Endocrinology Hyperthyroidism Ca Thyroid IODINE-131 Pheochromocytoma Paraganglioma Carcinoid IODINE-131 - mIBG Intracavitary Synovectomy (microspheres) YTTRIUM-90 Resistent PAIN Ca Prostate Possibly others STRONTIUM-89 SAMARIUM-153 RADIOPHARMACEUTICALS … therapeutic APPLICATIONS

More Related